_id
690f3a61ccc777a4e85d1947
Ticker
BYSI
Name
BeyondSpring Inc
Exchange
NASDAQ
Address
100 Campus Drive, Florham Park, NJ, United States, 07932
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://beyondspringpharma.com
Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
Last Close
2.18
Volume
19970
Current Price
2.11
Change
-3.2110091743119393
Last Updated
2025-11-29T11:04:50.812Z
Image
data:image/webp;base64,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
Ipo Date
2017-03-09T00:00:00.000Z
Market Cap
83084576
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Rating
5
Target Price
1.25
Strong Buy
1
Buy
0
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
21000
Gross Profit
-21000
Operating Expenses
1769000
Operating Income
-1790000
Interest Expense
-
Pretax Income
-1717000
Net Income
-1540000
Eps
-0.03819703449137647
Dividends Per Share
-
Shares Outstanding
40332320
Income Tax Expense
26000
EBITDA
-1696000
Operating Margin
-
Total Other Income Expense Net
73000
Cash
12483000
Short Term Investments
141000
Receivables
-
Inventories
-
Total Current Assets
24411000
Property Plant Equipment
552000
Total Assets
29484000
Payables
304000
Short Term Debt
313000
Long Term Debt
-
Total Liabilities
49294000
Equity
-31775000
Depreciation
21000
Change In Working Capital
314178
Cash From Operations
-4291975
Capital Expenditures
294.83
Cash From Investing
1615522
Cash From Financing
279478
Net Change In Cash
2939000
PE
-
PB
-2.81047188638867
ROE
4.846577498033045
ROA
-5.223171889838556
FCF
-4292269.83
Fcf Percent
-
Piotroski FScore
0
Health Score
26
Deep Value Investing Score
1.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
4.3
Garp Investing Score
0.5
Growth Investing Score
0.5
Momentum Investing Score
5
Net Net Investing Score
0.5
Quality Investing Score
1
Value Investing Score
1
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
21000
Quarters > 0 > income Statement > gross Profit
-21000
Quarters > 0 > income Statement > operating Expenses
1769000
Quarters > 0 > income Statement > operating Income
-1790000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-1717000
Quarters > 0 > income Statement > net Income
-1540000
Quarters > 0 > income Statement > eps
-0.03819703449137647
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
40317266
Quarters > 0 > income Statement > income Tax Expense
26000
Quarters > 0 > income Statement > EBITDA
-1696000
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
73000
Quarters > 0 > balance Sheet > cash
12483000
Quarters > 0 > balance Sheet > short Term Investments
141000
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
24411000
Quarters > 0 > balance Sheet > property Plant Equipment
552000
Quarters > 0 > balance Sheet > total Assets
29484000
Quarters > 0 > balance Sheet > payables
304000
Quarters > 0 > balance Sheet > short Term Debt
313000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
49294000
Quarters > 0 > balance Sheet > equity
-31775000
Quarters > 0 > cash Flow > net Income
-1784000
Quarters > 0 > cash Flow > depreciation
21000
Quarters > 0 > cash Flow > change In Working Capital
314178
Quarters > 0 > cash Flow > cash From Operations
-4291975
Quarters > 0 > cash Flow > capital Expenditures
294.83
Quarters > 0 > cash Flow > cash From Investing
1615522
Quarters > 0 > cash Flow > cash From Financing
279478
Quarters > 0 > cash Flow > net Change In Cash
2939000
Quarters > 0 > ratios > PE
-0.03819703449137647
Quarters > 0 > ratios > PB
-2.81047188638867
Quarters > 0 > ratios > ROE
4.846577498033045
Quarters > 0 > ratios > ROA
-5.223171889838556
Quarters > 0 > ratios > FCF
-4292269.83
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
26
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
-
Quarters > 1 > income Statement > gross Profit
-
Quarters > 1 > income Statement > operating Expenses
1949000
Quarters > 1 > income Statement > operating Income
-1949000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-1856000
Quarters > 1 > income Statement > net Income
-1806000
Quarters > 1 > income Statement > eps
-0.044795755168130426
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
40316320
Quarters > 1 > income Statement > income Tax Expense
22000
Quarters > 1 > income Statement > EBITDA
-1867000
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
93000
Quarters > 1 > balance Sheet > cash
9544000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
25711000
Quarters > 1 > balance Sheet > property Plant Equipment
633000
Quarters > 1 > balance Sheet > total Assets
31043000
Quarters > 1 > balance Sheet > payables
266000
Quarters > 1 > balance Sheet > short Term Debt
307000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
48588000
Quarters > 1 > balance Sheet > equity
-30216000
Quarters > 1 > cash Flow > net Income
-1806000
Quarters > 1 > cash Flow > depreciation
82000
Quarters > 1 > cash Flow > change In Working Capital
-865000
Quarters > 1 > cash Flow > cash From Operations
-5874000
Quarters > 1 > cash Flow > capital Expenditures
146
Quarters > 1 > cash Flow > cash From Investing
10850000
Quarters > 1 > cash Flow > cash From Financing
-
Quarters > 1 > cash Flow > net Change In Cash
4969000
Quarters > 1 > ratios > PE
-0.044795755168130426
Quarters > 1 > ratios > PB
-2.955409346041832
Quarters > 1 > ratios > ROE
5.976965845909453
Quarters > 1 > ratios > ROA
-5.817736687820121
Quarters > 1 > ratios > FCF
-5874146
Quarters > 1 > ratios > Piotroski FScore
0
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
27
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
80000
Quarters > 2 > income Statement > gross Profit
-80000
Quarters > 2 > income Statement > operating Expenses
2610000
Quarters > 2 > income Statement > operating Income
-2610000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-2564000
Quarters > 2 > income Statement > net Income
4477000
Quarters > 2 > income Statement > eps
0.11104684157681058
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
40316320
Quarters > 2 > income Statement > income Tax Expense
20000
Quarters > 2 > income Statement > EBITDA
-2530000
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
46000
Quarters > 2 > balance Sheet > cash
6527000
Quarters > 2 > balance Sheet > short Term Investments
2000000
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
31526000
Quarters > 2 > balance Sheet > property Plant Equipment
713000
Quarters > 2 > balance Sheet > total Assets
37104000
Quarters > 2 > balance Sheet > payables
358000
Quarters > 2 > balance Sheet > short Term Debt
301000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
49771000
Quarters > 2 > balance Sheet > equity
-28309000
Quarters > 2 > cash Flow > net Income
-2509000
Quarters > 2 > cash Flow > depreciation
80000
Quarters > 2 > cash Flow > change In Working Capital
856000
Quarters > 2 > cash Flow > cash From Operations
-4452000
Quarters > 2 > cash Flow > capital Expenditures
49999
Quarters > 2 > cash Flow > cash From Investing
6304000
Quarters > 2 > cash Flow > cash From Financing
-
Quarters > 2 > cash Flow > net Change In Cash
-35098000
Quarters > 2 > ratios > PE
0.11104684157681058
Quarters > 2 > ratios > PB
-3.1544967607474654
Quarters > 2 > ratios > ROE
-15.814758557349254
Quarters > 2 > ratios > ROA
12.066084519189307
Quarters > 2 > ratios > FCF
-4501999
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
47
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
-1438000
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-1438000
Quarters > 3 > income Statement > operating Expenses
1700000
Quarters > 3 > income Statement > operating Income
-1700000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-1823000
Quarters > 3 > income Statement > net Income
-1729000
Quarters > 3 > income Statement > eps
-0.043515256552135465
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
39733191
Quarters > 3 > income Statement > income Tax Expense
96000
Quarters > 3 > income Statement > EBITDA
-1680000
Quarters > 3 > income Statement > operating Margin
118.21974965229485
Quarters > 3 > income Statement > total Other Income Expense Net
-123000
Quarters > 3 > balance Sheet > cash
2922000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
28577000
Quarters > 3 > balance Sheet > property Plant Equipment
752000
Quarters > 3 > balance Sheet > total Assets
34315000
Quarters > 3 > balance Sheet > payables
295000
Quarters > 3 > balance Sheet > short Term Debt
282000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
48600000
Quarters > 3 > balance Sheet > equity
-32900000
Quarters > 3 > cash Flow > net Income
-5278000
Quarters > 3 > cash Flow > depreciation
285000
Quarters > 3 > cash Flow > change In Working Capital
4494000
Quarters > 3 > cash Flow > cash From Operations
-16443000
Quarters > 3 > cash Flow > capital Expenditures
27000
Quarters > 3 > cash Flow > cash From Investing
-12012000
Quarters > 3 > cash Flow > cash From Financing
26785000
Quarters > 3 > cash Flow > net Change In Cash
-7014000
Quarters > 3 > ratios > PE
-0.043515256552135465
Quarters > 3 > ratios > PB
-2.6750461417933127
Quarters > 3 > ratios > ROE
5.25531914893617
Quarters > 3 > ratios > ROA
-5.038612851522658
Quarters > 3 > ratios > FCF
-16470000
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
11.453407510431154
Quarters > 3 > health Score
36
Valuation > metrics > PE
-0.03819703449137647
Valuation > metrics > PB
-2.81047188638867
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > metrics > ROE
4.846577498033045
Profitability > metrics > ROA
-6.308631354717136
Profitability > final Score
25
Profitability > verdict
Weak
Risk > metrics > Interest Coverage
-85.23809523809524
Risk > final Score
-311
Risk > verdict
High
Liquidity > metrics > Current Ratio
39.56401944894652
Liquidity > metrics > Quick Ratio
39.56401944894652
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
50
Prev Valuations > 1
70
Prev Valuations > 2
50
Prev Profitabilities > 0
27
Prev Profitabilities > 1
45
Prev Profitabilities > 2
41
Prev Risks > 0
-679
Prev Risks > 1
-277
Prev Risks > 2
-18
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-13T14:43:41.587Z
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ABYSI Stock Volatility Amidst Strategic Developments and Market Shifts StocksToTrade
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$1.25
Analyst Picks
Strong Buy
1
Buy
0
Hold
0
Sell
0
Strong Sell
0
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
* Institutions hold a combined 16.85% of the total shares of BeyondSpring Inc
1.
Decheng Capital LLC(11.2354%)
since
2025/06/30
2.
BlackRock Inc(1.5746%)
since
2025/06/30
3.
Vanguard Group Inc(1.2985%)
since
2025/06/30
4.
Vanguard Institutional Extnd Mkt Idx Tr(0.8539%)
since
2025/07/31
5.
Geode Capital Management, LLC(0.6353%)
since
2025/06/30
6.
Fidelity Extended Market Index(0.2205%)
since
2025/07/31
7.
Fidelity Total Market Index(0.1968%)
since
2025/07/31
8.
iShares Micro-Cap ETF(0.1623%)
since
2025/08/31
9.
Fidelity Series Total Market Index(0.1057%)
since
2025/07/31
10.
Extended Equity Market Fund K(0.1022%)
since
2025/06/30
11.
Tanaka Capital Management Inc(0.0652%)
since
2025/03/31
12.
Spartan Total Market Index Pool G(0.0594%)
since
2025/07/31
13.
Fidelity Nasdaq Composite Index(0.0585%)
since
2025/07/31
14.
Vanguard U.S. Eq Idx £ Acc(0.0555%)
since
2025/07/31
15.
Northern Trust Corp(0.0404%)
since
2025/06/30
16.
Renaissance Technologies Corp(0.0288%)
since
2025/06/30
17.
Morgan Stanley - Brokerage Accounts(0.0204%)
since
2025/06/30
18.
Bank of America Corp(0.0193%)
since
2025/06/30
19.
UBS Group AG(0.0172%)
since
2025/06/30
20.
1290 VT Micro Cap K(0.015%)
since
2025/07/31
21.
AVIP BlackRock Advtg Small Cp Gr Prtfl(0.0134%)
since
2025/06/30
22.
Northern Small Cap Core I(0.0132%)
since
2025/06/30
23.
Extended Equity Market Fund M(0.0129%)
since
2025/06/30
24.
Spartan Extended Market Index Pool F(0.012%)
since
2025/07/31
25.
BlackRock Advtg Asia ex Jpn Eq D GBP Acc(0.0083%)
since
2025/05/31
26.
NT Quality SCC US Fund - L(0.0077%)
since
2025/06/30
27.
NT Quality Small Cap Core(0.0077%)
since
2025/06/30
28.
Trifecta Capital Advisors LLC(0.0037%)
since
2025/06/30
29.
Steward Partners Investment Advisory, LLC(0.0027%)
since
2025/06/30
30.
Fidelity U.S. Equity Index Ins Trust(0.0012%)
since
2025/07/31
31.
Tower Research Capital LLC(0.0006%)
since
2025/06/30
32.
JPMorgan Chase & Co(0.0004%)
since
2025/06/30
33.
Guggenheim Active Allocation Fund(0.0003%)
since
2025/05/31
34.
SBI Securities Co Ltd(0.0002%)
since
2025/06/30
35.
BNP Paribas Arbitrage, SA(0%)
since
2025/06/30
36.
Barclays PLC(0%)
since
2025/03/31
37.
Wells Fargo & Co(0%)
since
2025/03/31
38.
Banque Transatlantique(0%)
since
2025/06/30
39.
Citadel Advisors Llc(0%)
since
2025/06/30
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.